Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | PPOX | P50336 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526398 | 0.95 | TSHR (0.53) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL5115680 | 0.86 | TSHR (0.51) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL10631279 | 0.86 | TSHR (0.44) | TSHRCES2CES1PPIAVCAM1 | |
| SCHEMBL26333958 | 0.86 | CA12 (0.47) | TSHRCES2CES1PPIAVCAM1 | |
| SCHEMBL8136865 | 0.85 | TSHR (0.58) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL1790306 | 0.85 | TSHR (0.49) | TSHRTDP1DTYMKVCAM1ALDH1A1 | |
| SCHEMBL8129334 | 0.85 | TSHR (0.58) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL11576391 | 0.85 | KMT2A (0.53) | TSHRPPIAVCAM1ALDH1A1CYP3A4 | |
| SCHEMBL613001 | 0.84 | ALDH1A1 (0.53) | TSHRDTYMKVCAM1ALDH1A1CYP3A4 | |
| SCHEMBL4180430 | 0.84 | TSHR (0.61) | TSHRTDP1L3MBTL1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4551560-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Huyabio International, LLC (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2023177591-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177591-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-10093663-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| EP-3299365-A1 | PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| WO-2013164802-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| CN-101883762-A | Benzothiazoles as modulators of growth hormone releasing hormone receptors | ASTRAZENECA AB | 2010-11-10 | — | — | CN | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | TSHR 256/4885TDP1 1302/4885L3MBTL1 2459/4885 |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | TSHR 35/4885TDP1 4366/4885L3MBTL1 1929/4885 |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | WDR5, WDR1, WDR3 | TSHR 4457/4885TDP1 2790/4885L3MBTL1 918/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | TSHR 230/4885TDP1 4230/4885L3MBTL1 771/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | TSHR 333/4885TDP1 4334/4885L3MBTL1 3499/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | TSHR 35/4885TDP1 4366/4885L3MBTL1 1929/4885 |
| US-10093663-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | CFB, C5, TFPI | TSHR 2710/4885TDP1 4507/4885L3MBTL1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.